Quotes 5-day view Delayed Nasdaq
01/15/2021
01/19/2021
01/20/2021
01/21/2021
01/22/2021
Date
158.54(c)
164.47(c)
158.6(c)
158.02(c)
164.33(c)
Last
279 040
252 491
272 291
193 351
170 625
Volume
-2.35%
+3.74%
-3.57%
-0.37%
+3.99%
Change
Sales 2020
17,9 M
-
-
Net income 2020
-126 M
-
-
Net cash position 2020
739 M
-
-
P/E ratio 2020
-61,1x
Yield 2020
-
Sales 2021
-
-
-
Net income 2021
-222 M
-
-
Net cash position 2021
728 M
-
-
P/E ratio 2021
-37,1x
Yield 2021
-
Capitalization
8 277 M
8 277 M
-
EV / Sales 2020
422x
EV / Sales 2021
-
Nbr of Employees
62
Free-Float
83,5%
Kodiak Sciences Inc. is a clinical stage biopharmaceutical company. The Company is focused on developing therapeutics to treat ophthalmic diseases. The Company’s Antibody Biopolymer Conjugate (ABC) platform focuses on merging the fields of antibody-based and chemistry-based therapies. The Company in addition to its lead product candidate, KSI-301, is a molecule for age-related macular degeneration and diabetic...
Notations Surperformance© of Kodiak Sciences Inc.
Trading Rating :
Investor Rating :
-
All news about KODIAK SCIENCES INC.
News in other languages on KODIAK SCIENCES INC.
Analyst Recommendations on KODIAK SCIENCES INC.
Chart KODIAK SCIENCES INC.
Duration :
Auto.
2 months
3 months
6 months
9 months
1 year
2 years
5 years
10 years
Max.
Period :
Day
Week
Technical analysis trends KODIAK SCIENCES INC.
Short Term Mid-Term Long Term Trends Bullish Bullish Bullish
Income Statement Evolution
Please enable JavaScript in your browser's settings to use dynamic charts.
Mean consensus
OUTPERFORM
Number of Analysts
11
Average target price
124,91 $
Last Close Price
164,33 $
Spread / Highest target
3,45%
Spread / Average Target
-24,0%
Spread / Lowest Target
-68,4%
Please enable JavaScript in your browser's settings to use dynamic charts.